Amniox is now BioTissue Surgical!

 

Our future journey is to bring strength to our organization, leaning on our unique pioneering heritage by bringing together BioTissue and Amniox, one company with one purpose and one vision. A single unified brand combining the unique power of both businesses. BioTissue Surgical better reflects our vision as the regenerative medicine pioneer and our goals for the future as a biologic’s provider to realize the full potential of regenerative therapy.

We are BioTissue. The most human form of healing.

Biological Tissue Provides the Most Human Form of Healing

We are in a race against time to heal surgical and chronic wounds. BioTissue Surgical products provide the natural healing properties of human birth tissue to the wound.

The Neox® line of human amniotic membrane allografts help support regenerative healing and functional recovery for a variety of wounds—ranging from common surgical wounds to complex chronic wounds.1-7

  • High closure rates2-7
  • Fewer applications2-7
  • Expedited healing while reducing the cost of care2-7

Neox 100 is a thinner cryopreserved version of our human amniotic membrane allograft, ideal for shallow wounds or for larger wound areas. The allograft is delivered on a non-implantable, gridded paper backing for easier handling and application.

Neox 1K is a cryopreserved ultra-thick human amniotic membrane derived from umbilical cord used as an adjunct treatment for chronic and acute, partial and full-thickness wounds.1,3-5 This allograft helps promote healing in complex diabetic foot ulcers complicated with osteomyelitis, comparing favorably to the Standard of Care.1,5,6 It’s up to 10 times thicker than amniotic membrane alone,7 which may increase longevity in the wound bed, potentially reducing applications and cost of care.

Neox RT is a sterile, ultra-thick human amniotic membrane allograft derived from umbilical cord, for chronic and acute partial and full thickness wounds. Neox RT delivers the benefits of human amniotic allograft in a shelf stable product with room temperature storage. It is manufactured, using the SteriTek® preservation process, stored in saline (0.9% w/v NaCl) and terminally sterilized via gamma irradiation yielding a hydrated shelf stable product.

The Clarix® line of human amniotic membrane allografts help support regenerative healing and functional recovery across a wide array of surgical wound and soft tissue applications as an adjunct. 10-21

Clarix 100 is a thinner cryopreserved version of our human amniotic membrane. Clarix 100 is ideal for surgical applications that favor a minimal approach/incision or where space is anatomically compromised. For easier handling and application, the allograft is delivered on a non-implantable, gridded paper backing which is removed at the time of application.

Clarix 1K is a cryopreserved ultra-thick human amniotic membrane derived from umbilical cord. Clarix 1K is used as a barrier or cushion to create a protective environment for healing in soft tissue repair and reconstruction as an adjunct. It’s up to 10X thicker than amniotic membrane alone,20 which may increase longevity in the surgical site.

Downloadable Resources

  • To access downloadable resources, kindly fill out the form below.
  • By clicking the button below, I agree to receive marketing communications from BioTissue. I am aware that I can unsubscribe at any time.


References:
1. Tseng SC. Invest Ophthalmol Vis Sci. 2016;57(5):ORSFh1-ORSFh8.
2. Caputo WJ, Vaquero C, Monterosa A, et al. Wound Repair Regen. 2016;24(5):885-893.
3. Couture M. Wounds. 2016;28(7):217-25.
4. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetes Care 2002; 25: 1835–9.
5. Fife CE, Eckert KA, Carter MJ. Adv Wound Care 2018; 7: 77–94.
6. Raphael A. J Wound Care. 2016;25(Sup7):S10-17.
7. Raphael A, Gonzales J. J Wound Care. 2017;26(Sup10):S38-44.
8. Cooke M, Tan EK, Mandrycky C, He H, O’Connell J, Tseng SC. J Wound Care. 2014;23(10):465-476.
9. Swan J. Surg Technol Int. 2014;25:73-78
10. Bemenderfer TB, Anderson RB, Odum SM, Davis WH. J Foot Ankle Surg. 2019;58(1):97-102.
11. DeMill SL, Granata JD, Berlet GC, et al. Surg Technol Int. 2014;25:257-61.
12. Ellington J, Ferguson C. Surg Technol Int. 2014;25:63–67.
13. Stewart CM. SunKrist J Trauma Emerg Med Acute Care. 2019;1(1):1-6.
14. Penner M, et al. Foot & Ankle Specialist. 2021 Jun;14(3):193-200.
15. Anderson DG, et al. Clinical spine surgery. 2017; 30: 413-8.
16. Warner M, Lasyone L. Surg Technol Int. 2014;25:251-5.
17. Covell DJ, et al. Foot & Ankle Orthopaedics. 2016; 1: 2473011416S00311.
18. Galli SH, et al. Foot & Ankle Orthopaedics. 2020 Jul 2;5(2):2473011420S00004.
19. Papanna R, et al. Obstet Gynecol. 2016 Aug;128(2):325-330.
20. Cooke M, Tan EK, Mandrycky C, He H, O’Connell J, Tseng SC. J Wound Care. 2014;23(10):465-476.